Integral Diagnostics (IDX.AX) Stock Price

Integral Diagnostics Price

ASX·CLOSED
2.10AUD-0.04 (-1.89 %)
Market closed

Over the last 12 years Integral Diagnostics grew revenue by 23.3% annually, reaching 627.97 M AUD. Earnings per share have declined at 6.4% per year over the last 12 years. For Integral Diagnostics, the net margin of 0.7% is down versus 8.9% a few years ago. At today's price the dividend yield works out to roughly 4.42%. The payout ratio is around 615% of earnings. The dividend has grown at 5.5% per year over the past 9 years. The consensus 12-month price target for Integral Diagnostics is 3.37 AUD, about 60.3% above where the stock trades today. Of 16 analysts, 14 rate the stock a buy — an overall Buy consensus. The stock trades about 8% above its 52-week low.

Integral Diagnostics stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Integral Diagnostics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Integral Diagnostics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Integral Diagnostics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Integral Diagnostics Stock Price History
DateIntegral Diagnostics Price
7/17/20262.10 AUD
7/16/20262.14 AUD
7/15/20262.10 AUD
7/14/20262.07 AUD
7/13/20262.08 AUD
7/10/20262.07 AUD
7/9/20262.08 AUD
7/8/20262.05 AUD
7/7/20262.10 AUD
7/6/20262.06 AUD
7/3/20262.03 AUD
7/2/20262.01 AUD
7/1/20262.01 AUD
6/30/20262.01 AUD
6/29/20262.02 AUD
6/26/20262.00 AUD
6/25/20262.01 AUD
6/24/20261.98 AUD
6/23/20261.97 AUD
6/22/20261.94 AUD
6/19/20261.96 AUD
6/18/20262.04 AUD
6/17/20262.07 AUD
6/16/20262.02 AUD
6/15/20262.07 AUD
6/12/20262.05 AUD
6/11/20262.03 AUD
6/10/20262.01 AUD
6/9/20262.00 AUD
6/5/20262.06 AUD
6/4/20262.03 AUD
6/3/20262.06 AUD
6/2/20262.12 AUD
6/1/20262.17 AUD
5/29/20262.12 AUD
5/28/20262.12 AUD
5/27/20262.08 AUD
5/26/20262.08 AUD
5/25/20262.08 AUD
5/22/20262.08 AUD
5/21/20262.03 AUD
5/20/20262.05 AUD
5/19/20262.08 AUD
5/18/20262.07 AUD
5/15/20262.11 AUD
5/14/20262.17 AUD
5/13/20262.19 AUD
5/12/20262.19 AUD
5/11/20262.22 AUD
5/8/20262.27 AUD
5/7/20262.31 AUD
5/6/20262.26 AUD
5/5/20262.23 AUD
5/4/20262.27 AUD
5/1/20262.22 AUD
4/30/20262.23 AUD
4/29/20262.19 AUD
4/28/20262.20 AUD
4/27/20262.23 AUD
4/24/20262.23 AUD
4/23/20262.20 AUD
4/22/20262.22 AUD
4/21/20262.30 AUD
4/20/20262.30 AUD
4/17/20262.26 AUD
4/16/20262.31 AUD
4/15/20262.28 AUD
4/14/20262.25 AUD
4/13/20262.25 AUD
4/10/20262.27 AUD
4/9/20262.27 AUD
4/8/20262.30 AUD
4/7/20262.26 AUD
4/2/20262.25 AUD
4/1/20262.32 AUD
3/31/20262.36 AUD
3/30/20262.35 AUD
3/27/20262.34 AUD
3/26/20262.39 AUD
3/25/20262.37 AUD
3/24/20262.38 AUD
3/23/20262.36 AUD
3/20/20262.41 AUD
3/19/20262.36 AUD
3/18/20262.39 AUD
3/17/20262.33 AUD
3/16/20262.31 AUD
3/13/20262.32 AUD
3/12/20262.30 AUD
3/11/20262.36 AUD
3/10/20262.36 AUD
3/9/20262.30 AUD
3/6/20262.36 AUD
3/5/20262.38 AUD
2/26/20262.45 AUD
2/25/20262.41 AUD
2/24/20262.27 AUD
2/23/20262.40 AUD
2/20/20262.41 AUD
2/19/20262.45 AUD
2/18/20262.42 AUD
2/17/20262.42 AUD
2/16/20262.44 AUD
2/13/20262.39 AUD
2/12/20262.47 AUD
2/11/20262.53 AUD
2/10/20262.49 AUD
2/9/20262.46 AUD
2/6/20262.43 AUD
2/5/20262.47 AUD
2/4/20262.49 AUD
2/3/20262.58 AUD
2/2/20262.58 AUD
1/30/20262.62 AUD
1/29/20262.65 AUD
1/28/20262.57 AUD
1/27/20262.61 AUD
1/23/20262.67 AUD
1/22/20262.64 AUD
1/21/20262.58 AUD
1/20/20262.59 AUD
1/19/20262.64 AUD
1/16/20262.61 AUD
1/15/20262.57 AUD
1/14/20262.65 AUD
1/13/20262.64 AUD
1/12/20262.60 AUD
1/9/20262.54 AUD
1/8/20262.54 AUD
1/7/20262.51 AUD
1/6/20262.51 AUD
1/5/20262.54 AUD
1/2/20262.51 AUD
12/31/20252.54 AUD
12/30/20252.46 AUD
12/29/20252.43 AUD
12/24/20252.45 AUD
12/23/20252.48 AUD
12/22/20252.43 AUD
12/19/20252.41 AUD
12/18/20252.41 AUD
12/17/20252.47 AUD
12/16/20252.47 AUD
12/15/20252.47 AUD
12/12/20252.45 AUD
12/11/20252.45 AUD
12/10/20252.48 AUD
12/9/20252.51 AUD
12/8/20252.46 AUD
12/5/20252.45 AUD
12/4/20252.47 AUD
12/3/20252.59 AUD
12/2/20252.58 AUD
12/1/20252.57 AUD
11/28/20252.62 AUD
11/27/20252.63 AUD
11/26/20252.65 AUD
11/25/20252.62 AUD
11/24/20252.57 AUD
11/21/20252.52 AUD
11/20/20252.56 AUD
11/19/20252.54 AUD
11/18/20252.52 AUD
11/17/20252.50 AUD
11/14/20252.49 AUD
11/13/20252.55 AUD
11/12/20252.58 AUD
11/11/20252.57 AUD
11/10/20252.57 AUD
11/7/20252.47 AUD
11/6/20252.50 AUD
11/5/20252.55 AUD
11/4/20252.61 AUD
11/3/20252.60 AUD
10/31/20252.59 AUD
10/30/20252.48 AUD
10/29/20252.55 AUD
10/28/20252.55 AUD
10/27/20252.58 AUD
10/24/20252.60 AUD
10/23/20252.58 AUD
10/22/20252.58 AUD
10/21/20252.60 AUD
10/20/20252.59 AUD
10/17/20252.57 AUD
10/16/20252.60 AUD
10/15/20252.62 AUD
10/14/20252.61 AUD
10/13/20252.65 AUD
10/10/20252.71 AUD
10/9/20252.74 AUD
10/8/20252.70 AUD
10/7/20252.70 AUD
10/6/20252.71 AUD
10/3/20252.73 AUD
10/2/20252.74 AUD
10/1/20252.76 AUD
9/30/20252.77 AUD
9/29/20252.78 AUD
9/26/20252.81 AUD
9/25/20252.85 AUD
9/24/20252.87 AUD
9/23/20252.87 AUD
9/22/20252.89 AUD
9/19/20252.92 AUD
9/18/20252.92 AUD
9/17/20252.85 AUD
9/16/20252.91 AUD
9/15/20252.89 AUD
9/12/20252.84 AUD
9/11/20252.82 AUD
9/10/20252.84 AUD
9/9/20252.84 AUD
9/8/20252.91 AUD
9/5/20252.89 AUD
9/4/20252.86 AUD
9/3/20252.85 AUD
9/2/20252.87 AUD
9/1/20252.89 AUD
8/29/20252.93 AUD
8/28/20252.94 AUD
8/27/20253.01 AUD
8/26/20253.06 AUD
8/25/20252.71 AUD
8/22/20252.68 AUD
8/21/20252.63 AUD
8/20/20252.69 AUD
8/19/20252.71 AUD
8/18/20252.71 AUD
8/15/20252.66 AUD
8/14/20252.69 AUD
8/13/20252.68 AUD
8/12/20252.72 AUD
8/11/20252.71 AUD
8/8/20252.76 AUD
8/7/20252.78 AUD
8/6/20252.74 AUD
8/5/20252.69 AUD
8/4/20252.68 AUD
8/1/20252.67 AUD
7/31/20252.67 AUD
7/30/20252.67 AUD
7/29/20252.72 AUD
7/28/20252.72 AUD
7/25/20252.75 AUD
7/24/20252.72 AUD
7/23/20252.67 AUD
7/22/20252.76 AUD
7/21/20252.67 AUD
Access this data via the Eulerpool API
Get Free API Key

Integral Diagnostics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
440.79 M AUD
39.83 M AUD
25.04 M AUD
Jan 1, 2024
469.70 M AUD
42.17 M AUD
-60.70 M AUD
Jan 1, 2025
627.97 M AUD
58.29 M AUD
4.67 M AUD
Jan 1, 2026 (e)
812.03 M AUD
96.98 M AUD
39.50 M AUD
Jan 1, 2027 (e)
863.18 M AUD
109.82 M AUD
47.26 M AUD
Jan 1, 2028 (e)
915.26 M AUD
123.59 M AUD
56.06 M AUD
Jan 1, 2029 (e)
946.91 M AUD
154.61 M AUD
64.20 M AUD
Jan 1, 2030 (e)
993.29 M AUD
160.19 M AUD
75.38 M AUD

Integral Diagnostics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 20, 2026, 10:47 AM
 
REVENUEB AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB AUD
EBITM AUD
EBIT MARGIN%
NET INCOMEM AUD
NET INCOME GROWTH%
DIV.AUD
DIV. GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
0.170.180.190.230.280.350.360.440.470.630.810.860.920.950.991.06
11.267.145.0022.7518.5327.272.8622.226.5933.6929.516.286.033.394.976.24
94.6495.0095.7795.2695.6495.1494.7295.2395.1095.5395.5395.5395.5395.5395.5395.53
0.160.170.180.220.260.330.340.420.450.600.780.820.870.900.951.01
26.0023.0028.0037.0048.0056.0038.0039.0042.0058.0096.00109.00123.00154.00160.00–
15.4812.7814.8115.9517.4516.0010.568.868.969.2511.8212.6313.4416.2816.11–
11.0015.0015.0020.0023.0031.0014.0025.00-60.004.0039.0047.0056.0064.0075.0080.00
175.0036.36–33.3315.0034.78-54.8478.57-340.00-106.67875.0020.5119.1514.2917.196.67
0.060.100.110.140.140.180.100.090.080.090.110.110.11–––
–66.6710.0027.27–28.57-44.44-10.00-11.1112.5022.22–––––
143.06149.57149.84162.87189.43202.99211.87235.80233.50310.22310.22310.22310.22310.22310.22310.22
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Integral Diagnostics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Integral Diagnostics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Integral Diagnostics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Integral Diagnostics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Integral Diagnostics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Integral Diagnostics stock margins

The Integral Diagnostics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Integral Diagnostics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Integral Diagnostics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
95.15 %
15.99 %
8.92 %
Jan 1, 2022
94.67 %
10.70 %
4.05 %
Jan 1, 2023
95.23 %
9.04 %
5.68 %
Jan 1, 2024
95.12 %
8.98 %
-12.92 %
Jan 1, 2025
95.52 %
9.28 %
0.74 %
Jan 1, 2026 (e)
95.52 %
11.94 %
4.86 %
Jan 1, 2027 (e)
95.52 %
12.72 %
5.48 %
Jan 1, 2028 (e)
95.52 %
13.50 %
6.12 %

Integral Diagnostics Stock Revenue, EBIT, Earnings per Share

The Integral Diagnostics earnings per share therefore indicates how much revenue Integral Diagnostics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
1.73 AUD
0.28 AUD
0.15 AUD
Jan 1, 2022
1.70 AUD
0.18 AUD
0.07 AUD
Jan 1, 2023
1.87 AUD
0.17 AUD
0.11 AUD
Jan 1, 2024
2.01 AUD
0.18 AUD
-0.26 AUD
Jan 1, 2025
2.02 AUD
0.19 AUD
0.02 AUD
Jan 1, 2026 (e)
2.62 AUD
0.31 AUD
0.13 AUD
Jan 1, 2027 (e)
2.78 AUD
0.35 AUD
0.15 AUD
Jan 1, 2028 (e)
2.95 AUD
0.40 AUD
0.18 AUD

Integral Diagnostics business model & stock analysis

Integral Diagnostics Ltd is an Australian company that has been providing medical imaging services for over 25 years. The company was founded in 1994 by Dr. Ian Kadish and a team of radiologists in Perth, Western Australia, offering radiology services to local clinics and hospitals. Over the years, Integral Diagnostics has expanded its services to provide imaging services nationwide. The business model of Integral Diagnostics is to deliver medical imaging to enable doctors and their patients to have a fast and accurate diagnosis. The company offers imaging services for a variety of medical specialties, including radiology, cardiology, obstetrics and gynecology, and neurology. They operate over 49 locations in Australia, many of which are in rural areas where access to medical care may be limited. Integral Diagnostics offers a wide range of products based on medical imaging. These include X-rays, mammography, ultrasound, CT scans, MRI scans, PET scans, and bone density scans. The company takes pride in being one of the few Australian medical imaging companies to offer a complete range of imaging services. Their services are conducted by qualified radiologists specialized in interpreting medical images. Integral Diagnostics also operates clinics for performing diagnostic and therapeutic procedures such as biopsies, drainages, and injections. These procedures are carried out by highly qualified radiologists to provide patients with faster and more accurate diagnoses. Integral Diagnostics is committed to quality assurance and has a comprehensive quality management system that is annually reviewed by independent auditors. The company is accredited by both the Australian Medical Association and the Australian National Accreditation Scheme (NATA). These accreditations recognize the high standards that Integral Diagnostics sets for delivering medical imaging services. One of Integral Diagnostics' recent activities is their use of artificial intelligence (AI) in image interpretation. The company has partnered with MaxQ AI, a leading provider of AI solutions for medical imaging. Through this partnership, Integral Diagnostics doctors can utilize the latest AI tools to improve their patients' diagnoses. Integral Diagnostics is a strong advocate for social justice and is dedicated to supporting disadvantaged communities in Australia. The company has partnered with nonprofit organizations such as the National Breast Cancer Foundation, The Smith Family, and the Friendship Foundation. Overall, Integral Diagnostics has undergone impressive growth over the past 25 years and is now a leading Australian medical imaging company. With a wide range of imaging services and a strong focus on quality and social responsibility, the company is well-positioned to continue its success in the future.

Integral Diagnostics SWOT Analysis

Strengths

Integral Diagnostics Ltd has several notable strengths that contribute to its success in the healthcare industry. Firstly, the company has an extensive network of medical imaging centers, allowing it to reach a wide customer base. This allows for increased market penetration and revenue generation. Additionally, Integral Diagnostics has a strong reputation for providing high-quality diagnostic services, which enhances its competitive advantage. The company also boasts a team of skilled and experienced medical professionals who provide accurate and reliable diagnoses, further solidifying its position in the market.

Despite its strengths, Integral Diagnostics Ltd faces several weaknesses that it needs to address. One weakness is the company's dependency on Medicare reimbursement rates for a significant portion of its revenue. This exposes the business to potential changes in government policies and regulations, which could negatively impact its financial performance. Another weakness is the limited geographical presence of Integral Diagnostics, primarily operating in Australia. This reduces its ability to capitalize on international market opportunities and diversify its revenue streams.

Integral Diagnostics Ltd has identified several opportunities for future growth. With the increasing demand for medical imaging services globally, the company can expand its operations internationally to tap into new markets. By leveraging advancements in technology, such as artificial intelligence and telemedicine, Integral Diagnostics can enhance its service offerings and improve efficiency. Furthermore, partnerships and collaborations with healthcare providers can lead to mutually beneficial arrangements and provide access to a larger patient population.

The healthcare industry poses various threats to Integral Diagnostics Ltd. One major threat is the potential disruption caused by new competitors entering the market with innovative diagnostic technologies or business models. This could challenge the company's market share and competitive position. Additionally, changes in healthcare policies and regulations, both domestically and internationally, could affect reimbursement rates and operational requirements, disrupting Integral Diagnostics' financial performance and operations. Lastly, economic downturns and declines in healthcare spending can impact the overall demand for medical imaging services, creating a threat to the company's revenue generation.

Weaknesses

Despite its strengths, Integral Diagnostics Ltd faces several weaknesses that it needs to address. One weakness is the company's dependency on Medicare reimbursement rates for a significant portion of its revenue. This exposes the business to potential changes in government policies and regulations, which could negatively impact its financial performance. Another weakness is the limited geographical presence of Integral Diagnostics, primarily operating in Australia. This reduces its ability to capitalize on international market opportunities and diversify its revenue streams.

Integral Diagnostics Ltd has identified several opportunities for future growth. With the increasing demand for medical imaging services globally, the company can expand its operations internationally to tap into new markets. By leveraging advancements in technology, such as artificial intelligence and telemedicine, Integral Diagnostics can enhance its service offerings and improve efficiency. Furthermore, partnerships and collaborations with healthcare providers can lead to mutually beneficial arrangements and provide access to a larger patient population.

The healthcare industry poses various threats to Integral Diagnostics Ltd. One major threat is the potential disruption caused by new competitors entering the market with innovative diagnostic technologies or business models. This could challenge the company's market share and competitive position. Additionally, changes in healthcare policies and regulations, both domestically and internationally, could affect reimbursement rates and operational requirements, disrupting Integral Diagnostics' financial performance and operations. Lastly, economic downturns and declines in healthcare spending can impact the overall demand for medical imaging services, creating a threat to the company's revenue generation.

Opportunities

Integral Diagnostics Ltd has identified several opportunities for future growth. With the increasing demand for medical imaging services globally, the company can expand its operations internationally to tap into new markets. By leveraging advancements in technology, such as artificial intelligence and telemedicine, Integral Diagnostics can enhance its service offerings and improve efficiency. Furthermore, partnerships and collaborations with healthcare providers can lead to mutually beneficial arrangements and provide access to a larger patient population.

The healthcare industry poses various threats to Integral Diagnostics Ltd. One major threat is the potential disruption caused by new competitors entering the market with innovative diagnostic technologies or business models. This could challenge the company's market share and competitive position. Additionally, changes in healthcare policies and regulations, both domestically and internationally, could affect reimbursement rates and operational requirements, disrupting Integral Diagnostics' financial performance and operations. Lastly, economic downturns and declines in healthcare spending can impact the overall demand for medical imaging services, creating a threat to the company's revenue generation.

Threats

The healthcare industry poses various threats to Integral Diagnostics Ltd. One major threat is the potential disruption caused by new competitors entering the market with innovative diagnostic technologies or business models. This could challenge the company's market share and competitive position. Additionally, changes in healthcare policies and regulations, both domestically and internationally, could affect reimbursement rates and operational requirements, disrupting Integral Diagnostics' financial performance and operations. Lastly, economic downturns and declines in healthcare spending can impact the overall demand for medical imaging services, creating a threat to the company's revenue generation.

Integral Diagnostics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Integral Diagnostics historical P/E ratio, EBIT multiple, and P/S ratio

Integral Diagnostics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Integral Diagnostics shares outstanding

The number of shares of Integral Diagnostics was 310.22 M in 2025. This indicates how many shares Integral Diagnostics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
202.99 M Stocks
Jan 1, 2022
211.87 M Stocks
Jan 1, 2023
235.80 M Stocks
Jan 1, 2024
233.50 M Stocks
Jan 1, 2025
310.22 M Stocks
Jan 1, 2026 (e)
310.22 M Stocks
Jan 1, 2027 (e)
310.22 M Stocks
Jan 1, 2028 (e)
310.22 M Stocks

Integral Diagnostics Dividend History

10 years of dividend payments

YearAnnual DividendYoY ChangePayments
20250.09AUD↑ 12.1%2×
Mar 6, 20250.04AUD↓ 24.2%1/2
Aug 29, 20250.06AUD↑ 60.0%2/2
20240.08AUD↓ 3.3%2×
20230.09AUD↓ 14.3%2×
20220.10AUD↓ 44.0%2×
20210.18AUD↑ 31.6%2×
20200.14AUD↓ 5.0%2×
20190.14AUD↑ 25.0%2×
20180.11AUD↑ 14.3%2×
20170.10AUD↑ 75.0%2×
20160.06AUD—1×

Integral Diagnostics dividend history and estimates

In 2025, Integral Diagnostics paid a dividend amounting to 0.09 AUD. Dividend means that Integral Diagnostics distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
0.18 AUD
0.00 AUD
Jan 1, 2022
0.10 AUD
0.00 AUD
Jan 1, 2023
0.09 AUD
0.00 AUD
Jan 1, 2024
0.08 AUD
0.00 AUD
Jan 1, 2025
0.09 AUD
0.00 AUD
Jan 1, 2026 (e)
0.06 AUD
0.06 AUD
Jan 1, 2027 (e)
0.00 AUD
0.11 AUD
Jan 1, 2028 (e)
0.00 AUD
0.11 AUD

Integral Diagnostics dividend payout ratio

In 2025, Integral Diagnostics had a payout ratio of 614.95%. The payout ratio indicates the percentage of the company's profits that Integral Diagnostics distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
114.49 %
Jan 1, 2022
145.14 %
Jan 1, 2023
80.71 %
Jan 1, 2024
-31.87 %
Jan 1, 2025
614.95 %
Jan 1, 2026 (e)
89.75 %
Jan 1, 2027 (e)
75.01 %
Jan 1, 2028 (e)
63.25 %

Current Integral Diagnostics forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
1.49 %
Buy87.50 % (14)
Hold6.25 % (1)
Sell6.25 % (1)
12M Price Target
3.37
Last Price
2.10
Currency
AUD
12M Return Potential
60.29 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the Integral Diagnostics stock

75/100
52
Environment
99
Social
74
Governance
E

Environment

20
Scope 1 - Direct Emissions750.3
Scope 2 - Indirect emissions from purchased energy8,753.5
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions9,503.8
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees75.47
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Integral Diagnostics shareholder structure

% Name
6.83418%
Yarra Funds Management Limited
Yarra Funds Management Limited
5.97360%
Challenger Ltd
Challenger Ltd
5.92440%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
3.73087%
Perpetual Investment Management Limited
Perpetual Investment Management Limited
2.97835%
Mitsubishi UFJ Financial Group Inc
Mitsubishi UFJ Financial Group Inc
2.20233%
Viburnum Funds Pty Ltd
Viburnum Funds Pty Ltd
...

Integral Diagnostics Executives and Management Board

IK

Dr. Ian Kadish

Chief Executive Officer, Managing Director, Executive Director · since 2017

Compensation1.25 M AUD
CW

Mr. Craig White

Chief Financial Officer

Compensation917,785.00 AUD
MM

Dr. Manish Mittal

Radiologist Executive Director · since 2025

Compensation347,945.00 AUD
TH

Mr. Toby Hall

Independent Non-Executive Director and Chair Elect

Compensation250,458.00 AUD
RM

Ms. Raelene Murphy

Non-Executive Independent Director

Compensation150,000.00 AUD

Frequently asked questions about Integral Diagnostics

The business model of Integral Diagnostics Ltd is focused on providing comprehensive diagnostic imaging services to the medical industry. They operate a network of medical imaging clinics across Australia, offering a wide range of imaging services such as MRI, CT, ultrasound, and X-ray scans. Integral Diagnostics aims to deliver high-quality radiology services, ensuring accurate and timely diagnosis for patients. Through their state-of-the-art facilities and experienced medical professionals, they aim to consistently meet the growing demand for advanced imaging services. Integral Diagnostics Ltd aims to enhance patient care and support healthcare providers in delivering effective treatment plans.

All fundamentals and in-depth analysis of Integral Diagnostics

Our stock analysis for Integral Diagnostics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Integral Diagnostics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Integral Diagnostics Stock
Integral Diagnostics Revenue→
Integral Diagnostics Stock
Integral Diagnostics Net Income→
Integral Diagnostics Stock
Integral Diagnostics P/E→
Integral Diagnostics Stock
Integral Diagnostics P/S→
Integral Diagnostics Stock
Integral Diagnostics EBIT→
Integral Diagnostics Stock
Integral Diagnostics Dividend→
Integral Diagnostics Stock
Integral Diagnostics Directors Dealings→
Integral Diagnostics Stock
Integral Diagnostics Stocks→
Integral Diagnostics Stock
Integral Diagnostics Market capitalization→
Integral Diagnostics Stock
Integral Diagnostics Debt→
Integral Diagnostics Stock
Integral Diagnostics Liabilities→
Integral Diagnostics Stock
Integral Diagnostics Equity→
Integral Diagnostics Stock
Integral Diagnostics AAQS→
Integral Diagnostics Stock
Integral Diagnostics Employees→
Integral Diagnostics Stock
Integral Diagnostics ROE→
Integral Diagnostics Stock
Integral Diagnostics ROA→
Integral Diagnostics Stock
Integral Diagnostics ROCE→
Integral Diagnostics Stock
Integral Diagnostics News→
Integral Diagnostics Stock
Integral Diagnostics Analyst Price Targets→

Health Stocks

Integrated Diagnostics HoldingsIntegragenIntegrumIntegra Lifesciences HoldingsIntelicare HoldingsInteger HoldingsIntellia TherapeuticsIntech BiopharmIntelligent Bio SolutionsIntco Medical Technology CoIntensity TherapeuticsIntai TechnologyAll Stocks A–Z →